(New page: {{BioPsy}} {{drugbox | IUPAC_name = 3-Bromo-N-[ [(''2S'')-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxy-benzamide | image = Remoxipride.png | CAS_number = 117591-7...) |
No edit summary |
||
Line 29: | Line 29: | ||
== Clinical trials == |
== Clinical trials == |
||
− | Remoxipride is a selective [[Dopamine receptor|D2]] [[Receptor antagonist|antagonist]], with a relatively low effective dosage and low incidence of side effects relative to [[haloperidol]]. However, after its introduction in Europe, its use was correlated with incidence of |
+ | Remoxipride is a selective [[Dopamine receptor|D2]] [[Receptor antagonist|antagonist]], with a relatively low effective dosage and low incidence of side effects relative to [[haloperidol]]. However, after its introduction in Europe, its use was correlated with incidence of aplastic anemia in as many as 1 in 10,000 cases, and it was taken off the market until its relationship to this possible side effect could be studied. |
== External links == |
== External links == |
Latest revision as of 23:02, 13 September 2007
Assessment |
Biopsychology |
Comparative |
Cognitive |
Developmental |
Language |
Individual differences |
Personality |
Philosophy |
Social |
Methods |
Statistics |
Clinical |
Educational |
Industrial |
Professional items |
World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
3-Bromo-N-[ [(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxy-benzamide IUPAC name | |
CAS number 117591-79-4 |
ATC code |
PubChem 54477 |
DrugBank [1] |
Chemical formula | |
Molecular weight | 371.27 g/mol |
Bioavailability | C16H23BrN2O3 |
Metabolism | |
Elimination half-life | |
Excretion | |
Pregnancy category | |
Legal status | |
Routes of administration |
Remoxipride is a substituted benzamide which was a promising antipsychotic during clinical trials in the 1990s, but was removed due to possible side effects.
Clinical trials
Remoxipride is a selective D2 antagonist, with a relatively low effective dosage and low incidence of side effects relative to haloperidol. However, after its introduction in Europe, its use was correlated with incidence of aplastic anemia in as many as 1 in 10,000 cases, and it was taken off the market until its relationship to this possible side effect could be studied.
External links
This page uses Creative Commons Licensed content from Wikipedia (view authors). |